611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Health Tip: Recognizing a Staph InfectionIs Dairy Fat Different?CDC Recommends Catch-Up HPV Vaccination for Young AdultsHow to Relieve Dry, Irritated EyesPretomanid Approved for Treatment of Drug-Resistant TBAHA News: Tiring Easily May Warn of Future Heart TroubleAmerica's Obesity Epidemic May Mean Some Cancers Are Striking SoonerHeavy Smog as Bad as Pack-a-Day Smoking for LungsConcussed NFL Players Sidelined for Much Longer NowadaysHormone Therapy for Prostate Cancer Might Harm the Heart: StudyObesity and 'Spare Tire' Raise Hispanics' Odds for Early DeathAHA News: Protein Made During Long Workouts May Warn of Heart ProblemsHow to Help Your Heart Weather Extreme HeatHealth Threats Don't End for Some Sepsis SurvivorsHeat Waves Brought by Climate Change Could Prove Deadly for Kidney PatientsHealth Tip: Avoiding AnemiaAre You Still Putting Off Colon Cancer Screening?Tips for Preventing DiverticulitisFDA Reports More Seizures Among VapersKids Getting Too Many Opioids After TonsillectomyCan Major Surgeries Cause a Long-Term 'Brain Drain'?How Much Coffee Is Too Much for Migraine Sufferers?Steady Stream of Lesser Head Hits in Football Can Still Damage BrainDon't Sweat It: Hyperhydrosis Can Be TreatedFast-Food Joints on Your Way to Work? Your Waistline May WidenAdults Need Vaccines, TooHealth Tip: Managing Arthritis of the Hands'Selfies' Might Someday Track Your Blood PressureIn Heat Waves, Fans May Do More Harm Than GoodSmoking Creates Long-Lasting Risk for Clogged Leg ArteriesFootball Head Trauma Linked Again to Long-Term Brain DamageDrug Approved to Treat Tenosynovial Giant Cell TumorRugby-Style Tackling Might Make Football SaferFor Kids With Asthma, Allergies, New School Year Can Bring Flare-UpsFrailty Not a Normal Part of AgingAHA News: Hurricane Checklist: Batteries, Bottled Water – And A Plan for Heart CareDangerous Sesame Allergy Affects Many AmericansScorching Pavement Sends Some to the ER With BurnsHealth Tip: Living With Hypoglycemia3-D Printers Might Someday Make Replacement HeartsCDC Renews Pledge to Fight Ebola Outbreak in AfricaAnemia Linked to Higher Odds for Dementia in SeniorsDrug Duo May Be an Advance Against a Common LeukemiaAHA News: Chemical Widely Used in Medical Plastic Alters Heart Function in Lab TestsHigh Blood Pressure Much More Deadly for the PoorHealth Tip: Understanding PrediabetesMild Head Injury Can Impair Your Sense of SmellMiddle Age Now a High-Risk Time for Bad FallsSmoking May Interfere With 'Embolization' Lung TreatmentHeartburn Drugs Might Bring Allergy Woes
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Blood Test Could Spot Multiple Cancer Types, Researchers Say

HealthDay News
by -- E.J. Mundell
Updated: May 29th 2019

new article illustration

WEDNESDAY, May 29, 2019 (HealthDay News) -- A gene-based blood test can accurately detect breast, colorectal, lung, ovarian, pancreatic, gastric or bile duct cancers in patients, researchers report.

The test uses artificial intelligence to identify and interpret "fragments" of DNA in the blood that indicate the presence of cancer, explained researchers led by Dr. Victor Velculescu. He helps direct the Cancer Biology Program at the Johns Hopkins Kimmel Cancer Center in Baltimore.

In the new study, the test -- called DELFI (DNA evaluation of fragments for early interception) -- accurately detected cancer in 73% of cancer patients overall, and only misclassified four out of 215 patients, meaning it had just a 2% error rate.

"DELFI helps identify the presence of cancer by detecting abnormalities in the size and amount of DNA in different regions of the genome based on how it is packaged," said lead author Jillian Phallen, a postdoctoral fellow at the Kimmel Cancer Center.

Still, this is just a proof-of-concept study, the researchers said, and more research is needed before it reaches routine use.

But such "liquid biopsies" are a holy grail of cancer research, potentially making cancer diagnosis easier and faster, and avoiding the need for invasive tissue biopsies.

Many blood-based biopsies are under development, but DELFI relies on a slightly different strategy than most. According to the Hopkins team, the test examines the way DNA is packaged within the cell nucleus. While healthy cells package their DNA in ordered, predictable ways, cancer cells do not -- instead, DNA appears more disordered and random.

This "means that when cancer cells die they release their DNA in a chaotic manner into the bloodstream," Phallen explained in a Hopkins news release. And it's these disorganized bits of DNA that the new test detects.

In the new trial, involving 208 cancer patients, DELFI accurately spotted one of seven cancers between 57% and 99% of the time in blood samples, the team reported May 29 in the journal Nature.

The study group included 54 breast cancer patients, 27 colorectal cancer patients, 12 lung cancer patients, 28 ovarian cancer patients, 34 pancreatic cancer patients, 27 gastric cancer patients and 26 bile duct cancer patients.

Genomic testing from these patients was compared to results from a comparison group of 215 healthy individuals.

As expected, the DNA fragmentation "profiles" of the healthy individuals were more ordered and much less variable than those of the cancer patients.

Besides simply spotting the presence of a cancer, the new blood test was between 61% and 75% accurate in determining the tissue of origin of the tumor, the study authors reported.

And when data from DELFI was added to another mutation-based analysis of "cell-free" DNA, this analysis accurately spotted tumors in 91% of the cancer patients, the investigators found.

This research remains in its early stage. However, "we're encouraged about the potential of DELFI because it looks at a completely independent set of cell-free DNA characteristics from those that have posed difficulties over the years," Velculescu said. "We look forward to working with our collaborators worldwide to make this test available to patients."

The researchers added that because the blood test is easy to administer and analyze in the lab, it could also prove to be a cost-saver.

More information

For current guidelines on cancer screening, head to the American Cancer Society.